Hence, T2D therapy has evolved from monotherapy using insulin, insulin secretagogues, or sensitizers alone to combination therapy using insulin/insulin secretagogues plus sensitizers and/or incretin-based drugs. The gene discussed is INS; the disease is type 2 diabetes mellitus.